Markus Joerger
Impact in
- Pharmacology top 0.2%
- Pharmacogenetics and Drug Metabolism
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
Papers in
- Oncology 86
- Cancer Immunotherapy and Biomarkers 37
- Cancer Treatment and Pharmacology 20
- Lung Cancer Research Studies 8
- Pharmacology 39
- Pharmacogenetics and Drug Metabolism 38
- Co-authors
- Jan H.M. Schellens (24 shared papers)Alwin D. R. Huitema (21 shared papers)Jos H. Beijnen (21 shared papers)Silke Gillessen (15 shared papers)Carlo Rodolfo Largiadèr (14 shared papers)Nicole Hagner (1 shared paper)Thomas Cerny (14 shared papers)Martin Früh (20 shared papers)
- Journals
- Annals of Oncology (23 papers)Cancer Chemotherapy and Pharmacology (13 papers)Lung Cancer (9 papers)European Journal of Cancer (7 papers)British Journal of Clinical Pharmacology (7 papers)
- Partner nations
- SwitzerlandGermanyNetherlands
In The Last Decade
Markus Joerger
202 papers receiving 5.8k citations
Markus Joerger's Hit Papers
Peers
Comparison fields: 5 of 123
- Pharmacology 974
- Oncology 1.6k
- Cancer Research 486
- Pulmonary and Respiratory Medicine 976
- Pediatrics, Perinatology and Child Health 319
Countries citing papers authored by Markus Joerger
This map shows the geographic impact of Markus Joerger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Joerger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Joerger more than expected).
Fields of papers citing papers by Markus Joerger
This network shows the impact of papers produced by Markus Joerger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Joerger. The network helps show where Markus Joerger may publish in the future.
Co-authors
The 25 scholars most cited alongside Markus Joerger, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 214 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Rapid mass spectrometric conversion of tissue biopsy samples into permanent quantitative digital proteome maps Hit paper breakdown → | 2015 | 319 |
| 2 | SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial Hit paper breakdown → | 2021 | 254 |
| 3 | 2004 | 235 | |
| 4 | 2019 | 148 | |
| 5 | 2010 | 127 | |
| 6 | 2014 | 124 | |
| 7 | 2009 | 121 | |
| 8 | 2006 | 101 | |
| 9 | 2007 | 101 | |
| 10 | 2023 | 100 | |
| 11 | 2018 | 99 | |
| 12 | 2005 | 95 | |
| 13 | 2017 | 95 | |
| 14 | 2012 | 82 | |
| 15 | 2019 | 82 | |
| 16 | 2002 | 80 | |
| 17 | 2010 | 80 | |
| 18 | 2016 | 78 | |
| 19 | 2010 | 76 | |
| 20 | 2016 | 76 |
About Markus Joerger
Markus Joerger is a scholar working on Oncology, Pharmacology, Pulmonary and Respiratory Medicine, Pediatrics, Perinatology and Child Health and Cancer Research, having authored 214 papers that have together received 5.9k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (38 papers), Cancer Immunotherapy and Biomarkers (37 papers), Cancer Treatment and Pharmacology (20 papers), Lung Cancer Treatments and Mutations (19 papers), Pharmaceutical studies and practices (17 papers), Lung Cancer Diagnosis and Treatment (13 papers), Breast Cancer Treatment Studies (12 papers) and Lung Cancer Research Studies (8 papers). The work is most often cited by research in Pharmacology (974 citations), Oncology (1.6k citations), Cancer Research (486 citations), Pulmonary and Respiratory Medicine (976 citations) and Pediatrics, Perinatology and Child Health (319 citations). Markus Joerger has collaborated with scholars based in Switzerland, Germany and Netherlands. Frequent co-authors include Jan H.M. Schellens, Alwin D. R. Huitema, Jos H. Beijnen, Silke Gillessen, Carlo Rodolfo Largiadèr, Nicole Hagner, Thomas Cerny, Martin Früh, Ursula Amstutz and Tanja K. Froehlich. Their work appears in journals such as Annals of Oncology, Cancer Chemotherapy and Pharmacology, Lung Cancer, European Journal of Cancer and British Journal of Clinical Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.